Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Rigel Pharmaceuticals, Inc.Rigel to Participate in Upcoming September Investor ConferencesRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the...
- Encapsulated Lactic Acid Market Analysis Report 2026-2031 - Advanced Coating Technologies Expand Specialty ApplicationsOpportunities center on nutraceuticals, probiotics, liquid formats and clean-label plant coatings, while controlled-release innovation expands food, beverage and pharmaceutical uses
- NewAmsterdam PharmaNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in SeptemberNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
- Annexon BiosciencesAnnexon to Participate in Upcoming September Investor ConferencesAnnexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:
- HYTN Announces Arrangement Agreement to Facilitate the Spin-Out of a Peptide-Focused Drug Development BusinessHYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, announces that it has entered into an arrangement agreement with Peptide Development Labs Inc. (“PDL”) dated September 1, 2026 (the “Arrangement Agreement”), pursuant to which HYTN will separate its peptide-focused drug development business centered on the pre-clinical development of a subcutaneous injectable BPC-157 drug candidate for refractory ligament disorders into PDL (the “Arrangement”). HYTN’s Board of Directors formed a special committee, which recommended approving the Arrangement and the Board in turn unanimously approved the Arrangement and Arrangement Agreement. Shareholders of HYTN (“Shareholders”) will receive common shares in PDL (“PDL Common Shares”) in proportion to their shareholdings in HYTN. HYTN currently holds approximately 17% of PDL and, after PDL completes a concurrent financing, the Shareholders are expected to own approximately 14% of PDL.
- Geron CorporationGeron to Present at Upcoming Investor ConferencesGeron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:
- ASCENTAGEAscentage Pharma to Participate in Four Upcoming Investor ConferencesAscentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York.
- vTv Therapeutics Inc.vTv Therapeutics to Participate in September Investor ConferencesvTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:
- Disc Medicine IncDisc Medicine to Participate in Upcoming Investor ConferencesDisc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:
- BioAge Labs, Inc.BioAge Labs to Present at Upcoming Investor ConferencesBioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
- Innoviva, Inc.Innoviva to Participate in Upcoming Investor ConferencesBURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:
- CG Oncology Inc.CG Oncology to Present at Upcoming Investor Conferences in SeptemberCG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows: